

# Erythropoetin in der Onkologie

Ulrich Dührsen, Essen

## Literatur

- Krantz SB. Erythropoietin. *Blood* 1991;77:419–34.
- Welch HG, Meehan KR, Goodnough LT. Prudent strategies for elective red blood cell transfusion. *Ann Intern Med* 1992;116:393–402.
- Smaniotta D, Luzi S, Morganti AG, Cellini N. Prognostic significance of anaemia and role of erythropoietin in radiation therapy. *Tumori* 2000;86:17–23.
- Harris AL. Hypoxia – a key regulatory factor in tumour growth. *Nat Rev Cancer* 2002;2:38–47.
- Dührsen U, Hossfeld DK. Hematopoietic growth factors and the treatment of tumor-associated anaemias. *Ann Hematol* 1994;69:213–21.
- Rote Liste® Service GmbH (ed.). Rote Liste® 2004. Aulendorf: Editio Cantor Verlag, 2004.
- Platanias LC, Miller CB, Mick R, Hart RD, et al. Treatment of chemotherapy-induced anaemia with recombinant human erythropoietin in cancer patients. *J Clin Oncol* 1991;9:2021–6.
- Miller CB, Platanias LC, Mills SR, Zahurak ML, et al. Phase I-II trial of erythropoietin in the treatment of cisplatin-associated anaemia. *J Natl Cancer Inst* 1992;84:98–103.
- Cazzola M, Messinger D, Battistel V, Bron D, et al. Recombinant human erythropoietin in the anaemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. *Blood* 1995;86:4446–53.
- Österborg A, Boogaerts MA, Cimino R, Essers U, et al. Recombinant human erythropoietin in transfusion-dependent anaemic patients with multiple myeloma and non-Hodgkin's lymphoma – a randomized multicenter study. The European study group of erythropoietin (epoetin beta) treatment in multiple myeloma and non-Hodgkin's lymphoma. *Blood* 1996;87:2675–82.
- Glaspy J, Bukowski R, Steinberg D, Taylor C, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit study group. *J Clin Oncol* 1997;15:1218–34.
- Demetri GD, Kris M, Wade J, Degos L, et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit study group. *J Clin Oncol* 1998;16:3412–25.
- Glaspy J, Jadeja JS, Justice G, Kessler J, et al. A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. *Br J Cancer* 2001;84(Suppl 1):17–23.
- Österborg A, Brandberg Y, Molostova V, Iosava G, et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. *J Clin Oncol* 2002;20:2486–94.
- Boogaerts M, Coiffier B, Kainz C. Impact of epoetin beta on quality of life in patients with malignant disease. *Br J Cancer* 2003;88:988–95.
- Dührsen U. The clinical value of erythropoietin in patients with cancer. *Drugs* 2002;62:2013–23.
- Dührsen U. Gibt es Indikationen für Erythropoetin in der Onkologie? *Dtsch Ärztebl* 2002;99:A3470–5.
- Abels RI. Recombinant human erythropoietin in the treatment of the anaemia of cancer. *Acta Haematol* 1992;87(Suppl 1):4–11.
- Lavey RS, Dempsey WH. Erythropoietin increases hemoglobin in cancer patients during radiation therapy. *Int J Radiat Oncol Biol Phys* 1993;27:1147–52.
- Sweeney PJ, Nicolae D, Ignacio L, Chen L, et al. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final report of a randomized, open-labelled, phase II trial. *Br J Cancer* 1998;77:1996–2002.
- A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Italian cooperative study group for rHuEpo in myelodysplastic syndromes. *Br J Haematol* 1998;103:1070–4.
- Negrin RS, Stein R, Vardiman J, Doherty K, et al. Treatment of the anaemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. *Blood* 1993;82:737–43.
- Hellström-Lindberg E, Ahlgren T, Beguin Y, Carlsson M, et al. Treatment of anaemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. *Blood* 1998;92:68–75.
- Mantovani L, Lentini G, Hentschel B, Wickramanayake PD, et al. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin. *Br J Haematol* 2000;109:367–75.
- Cazzola M, Beguin Y, Kloczko J, Spicka I, et al. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. *Br J Haematol* 2003;122:386–93.
- Glaspy JA, Jadeja JS, Justice G, Kessler J, et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. *Br J Cancer* 2002;87:268–76.
- Smith RE Jr, Tchekmedyan NS, Chan D, Meza LA, et al. A dose- and schedule-finding study of darbepoetin alfa for the treatment of chronic anaemia of cancer. *Br J Cancer* 2003;88:1851–8.
- Kotasek D, Steger G, Faught W, Underhill C, et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. *Eur J Cancer* 2003;39:2026–34.
- Cazzola M, Ponchio L, Pedrotti C, Farina G, et al. Prediction of response to recombinant human erythropoietin (rHuEpo) in anaemia of malignancy. *Haematologica* 1996;81:434–41.
- Hellström-Lindberg E, Negrin R, Stein R, Krantz S, et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. *Br J Haematol* 1997;99:344–51.
- Yellen SB, Cella DF, Webster K, Blendowski C, et al. Measuring fatigue and other anaemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system. *J Pain Symptom Manage* 1997;13:63–74.
- Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. *J Clin Oncol* 2001;19:2865–74.
- Dammacco F, Castoldi G, Rodjer S. Efficacy

Prof. Dr. med. Ulrich Dührsen, Klinik für Hämatologie, Universitätsklinikum Essen, Hufelandstraße 55, 45122 Essen, E-Mail: ulrich.duehresen@uni-essen.de

- of epoetin alfa in the treatment of anaemia of multiple myeloma. *Br J Haematol* 2001;113:172–9.
34. Vansteenkiste J, Pirker R, Massuti B, Barata F, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. *J Natl Cancer Inst* 2002;94:1211–20.
  35. Hedenus M, Adriansson M, San Miguel J, Kramer MH, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. *Br J Haematol* 2003;122:394–403.
  36. Crawford J, Cella D, Cleeland CS, Cremieux PY, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. *Cancer* 2002;95:888–95.
  37. Fallowfield L, Gagnon D, Zagari M, Cella D, et al. Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy. *Br J Cancer* 2002;87:1341–53.
  38. Bottomley A, Thomas R, van Steen K, Flechtner H, et al. Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about? *Lancet Oncol* 2002;3:145–53.
  39. Bush RS. The significance of anaemia in clinical radiation therapy. *Int J Radiat Oncol Biol Phys* 1986;12:2047–50.
  40. Glaser CM, Millesi W, Kornek GV, Lang S, et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. *Int J Radiat Oncol Biol Phys* 2001;50:705–15.
  41. Henke M, Laszig R, Rube C, Schafer U, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. *Lancet* 2003;362:1255–60.
  42. Cerami A. Beyond erythropoiesis: Novel applications for recombinant human erythropoietin. *Semin Hematol* 2001;38(Suppl 7):33–9.
  43. Ortega A, Dranitsaris G, Puodziunas AL. What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis. *Cancer* 1998;83:2588–96.
  44. Brandberg Y. Quality of life in clinical trials: assessment and utility with special reference to rHuEpo. *Med Oncol* 1998;15(Suppl I):8–12.
  45. Griggs JJ, Mushlin AI. Economic analysis of expensive technologies: the case of erythropoietin. *Cancer* 1998;83:2427–9.
  46. Barosi G, Marchetti M, Liberato NL. Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. *Br J Cancer* 1998;78:781–7.
  47. Cremieux P-Y, Finkelstein SN, Berndt ER, Crawford J, et al. Cost effectiveness, quality-adjusted life-years and supportive care. *Pharmacoeconomics* 1999;16:459–72.
  48. Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American society of clinical oncology and the American society of hematology. *Blood* 2002;100:2303–20.
  49. Llewelyn CA, Hewitt PE, Knight RS, Amar K, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. *Lancet* 2004;363:417–21.
  50. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. First of two parts – blood transfusion. *N Engl J Med* 1999;340:438–47.
  51. Goodnough LT. Erythropoietin therapy versus red cell transfusion. *Curr Opin Hematol* 2001;8:405–10.
  52. Oberhoff C, Neri B, Amadori D, Petry KU, et al. Recombinant human erythropoietin in the treatment of chemotherapy-induced anaemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. *Ann Oncol* 1998;9:255–60.
  53. Sheffield R, Sullivan SD, Saltiel E, Nishimura L. Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anaemia. *Ann Pharmacother* 1997;31:15–22.
  54. Meadowcroft AM, Gilbert CJ, Maravich-May D, Hayward SL. Cost of managing anaemia with and without prophylactic epoetin alfa therapy in breast cancer patients receiving combination chemotherapy. *Am J Health Syst Pharm* 1998;55:1898–1902.
  55. Kavanagh BD, Fischer BA, Segreti EM, Wheelock JB, et al. Cost analysis of erythropoietin versus blood transfusions for cervical cancer patients receiving chemoradiotherapy. *Int J Radiat Oncol Biol Phys* 2001;51:435–41.